JNJ-AbbVie cancer drug Imbruvica succeeds in late-stage trial

JNJ-AbbVie cancer drug Imbruvica succeeds in late-stage trial


Johnson and Johnson said on Tuesday a combination therapy containing its blockbuster cancer drug Imbruvica significantly improved survival in blood cancer patients, compared with drugs currently used as the standard of care. In the study, Imbruvica, jointly sold with AbbVie Inc, was given to newly diagnosed chronic lymphocytic leukemia patients aged 70 or younger, in combination with Roche AG's Rituxan.



from Biotech News